MIMEDX to Host Third Quarter 2021 Operating and Financial Results Conference Call on November 3

Rhea-AI Summary

MiMedx Group, Inc. (Nasdaq: MDXG) will announce its third-quarter financial results for the period ending September 30, 2021, on November 2, 2021, after market close. A webcast and conference call are scheduled for November 3, 2021, at 8:30 AM ET to discuss these results. MiMedx specializes in regenerative medicine, particularly through the use of amniotic tissue. The company has supplied over two million allografts, focusing on treating acute and chronic non-healing wounds while developing a pipeline for degenerative musculoskeletal conditions.

Positive

• MiMedx is a pioneer in placental biologics with significant market expertise.
• The company has supplied over two million allografts, indicating strong demand.
• MiMedx has a promising pipeline targeted at improving patient outcomes in musculoskeletal conditions.

Negative

• None.

MARIETTA, Ga., Oct. 20, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that it will report operating and financial results for the third quarter ended September 30, 2021 after the market close on Tuesday, November 2, 2021. MIMEDX management will host a webcast and conference call to review its results on Wednesday, November 3, 2021, beginning at 8:30 am Eastern Time.

The conference call can be accessed using the following information:

Webcast: Click here
U.S. Investors: 877-407-6184
International Investors: 201-389-0877
Conference ID: 13723750

A replay of the webcast will be available for approximately 30 days on the Company’s website at www.mimedx.com following the conclusion of the event.

About MIMEDX
MIMEDX is an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental biologics, we have both a base business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.

Contacts:
Investors
Jack Howarth
404-360-5681
jhowarth@mimedx.com

Corporate Communications
Hilary Dixon
404-323-4779
hdixon@mimedx.com

FAQ

When will MiMedx report its Q3 2021 earnings?

MiMedx will report its third-quarter earnings on November 2, 2021.

What time is the MiMedx conference call for Q3 2021 results?

The conference call will take place on November 3, 2021, at 8:30 AM ET.

What is the stock symbol for MiMedx?

The stock symbol for MiMedx is MDXG.

How can I access MiMedx's Q3 2021 earnings call?

You can access the earnings call via webcast or by phone at U.S. Investors: 877-407-6184.

What is MiMedx known for in the healthcare industry?

MiMedx is known for utilizing amniotic tissue in regenerative medicine, particularly for treating non-healing wounds.